Background Glycolysis is not completely or predictably inhibited by the glucose preservative currently in use, with glucose values falling by as much as 0.5 mmol/L during a 2-4-h period after sample collection. Immediate centrifugation of all samples is also impractical and therefore misdiagnosis of disease can occur, especially if more emphasis is being placed on fasting glucose for the diagnosis of diabetes.
Introduction
The World Health Organization (WHO) states: 1 Glucose concentrations should not be determined on serum unless red cells are immediately removed, otherwise glycolysis will result in an unpredictable underestimation of the true concentration. It should be stressed that glucose preservatives do not totally prevent glycolysis. If whole blood is used, the sample should be kept at 0 -48C or centrifuged immediately, or assayed immediately. ' It has long been recognized that glycolysis continues in whole blood even in the presence of sodium £uoride, the most commonly used preservative. 2, 3 This may lead to patients being misdiagnosed, 4 and is especially important now that more emphasis is being placed on measuring fasting blood glucose for the diagnosis of diabetes mellitus. 1 The issue of inadequate glucose preservation has been recognized for several years, 5, 6 but has not received the prominence it warrants, perhaps because of the practical problems it poses.
It is impractical to analyse all laboratory glucose samples immediately. Most clinical chemistry laboratories will deal with large numbers of glucose speci-mens per annum, and it is generally accepted that a routine sample may take several hours to reach the laboratory; hence the importance of inhibiting glycolysis. 2 Also, samples from general practitioners may travel considerable distances, rendering strict adherence to the WHO recommendations impossible.
Several inhibitors have been investigated. Sodium iodoacetate has been shown to inhibit glycolysis, but only for up to 2 h at room temperature. 7 Sodium £uoride slowed but did not eliminate glycolysis or the production of lactate, 8 plasma glucose values falling by as much as 0.5 mmol/ L over a 2-4-h period. 4 Recently, glyceraldehyde in combination with lithium-heparin has been found to be an alternative inhibitor of glycolysis, but this was only demonstrated for up to 8 h. 9 The aim of the present study was to examine the combination of glyceraldehyde with sodium £uoride as an inhibitor of glycolysis, and to evaluate its potential as a new antiglycolytic agent in a clinical setting.
Methods
All glucose measurements were performed in the laboratory on a single Olympus AU600 multichannel Original Article analyser using a hexokinase method. The betweenbatch coe¤cient of variation of glucose controls, with a target concentration of 3.48 mmol/ L measured over a 3-month period, was 2.6%. All additives were freezedried to the inside walls of tubes (to avoid dilutional e¡ects) in amounts such that the desired concentrations would be reached when 1mL of blood was added to each tube. Potassium oxalate (21.7 mmol) was included in all the sodium £uoride tubes as an anticoagulant. For each of the experiments enough blood for 1mL per tube was obtained from one individual. The tubes were centrifuged at the time points stated, and the plasma samples stored at 48C before assay. All measurements were done in triplicate.
Experiment 1 compared increasing amounts of glyceraldehyde (0, 4.7, 11, 20.4 mmol) in either plain tubes, in combination with lithium-heparin (143 units/tube), or in combination with sodium £uoride (119 mmol) added to 1-mL aliquots of venous blood from one individual. One tube from each set was centrifuged at 3 min, 4 h and 24 h after venesection.
Experiment 2 compared 11 mmol of glyceraldehyde alone with 119 mmol of sodium £uoride alone. Experi-ment 3 compared 119 mmol of sodium £uoride alone, 11 mmol of glyceraldehyde alone and the combination of 119 mmol of sodium £uoride with 11 mmol of glyceraldehyde over 11 time points covering a 48-h period. The e¡ectiveness of the combination was con¢rmed in experiment 4, using a lower initial plasma glucose concentration.
Parametric statistical analysis was performed using Sigmastat v2.0 (SPSS Science, Chicago IL, USA). Statistical comparisons were made using one-way analysis of variance. A probability level (P) of 0.05 (5%) or less was considered statistically signi¢cant. Table 1 indicates the mean concentrations of glucose stored in di¡erent amounts of glyceraldehyde for 0, 4 and 24 h at 48C. Tables 2 and 3 show corresponding data for tubes containing lithium-heparin and tubes containing sodium £uoride, respectively.
Results
There was a signi¢cant fall in glucose concentration, representing a failure to inhibit glycolysis, in all combinations except glyceraldehyde at a concentration of 4.7 mmol/ L or higher in the presence of 119 mmol/ L sodium £uoride (see Table 3 ). Experiment 2 con¢rmed the failure of either 11 mmol/ L glyceraldehyde alone or 119 mmol/ L sodium £uoride to prevent glycolysis (see Table 4 ). However, glucose concentrations in the samples in glyceraldehyde alone were signi¢cantly higher than the concentrations in the samples with sodium £uoride. Figures 1 and 2 re£ect experiments 3 and 4 and con¢rm the antiglycolytic e¡ectiveness of the combination of glyceraldehyde and sodium £uoride at glucose levels of 6.6 and 4.5 mmol/ L, respectively. Figure 1 gave erratic results, with the mean 4-h glucose concentration signi¢cantly less than that at the start (Pˆ0.005) or after 24 h (Pˆ0.005).
Discussion
Neither sodium £uoride, nor glyceraldehyde alone, nor glyceraldehyde in combination with lithiumheparin inhibits glycolysis completely. However, the combination of 11mmol/ L glyceraldehyde with 119 mmol/ L sodium £uoride inhibits glycolysis su¤ciently such that no loss of glucose was observed even after incubation for 24 h at room temperature prior to centrifugation. The glucose values obtained from this combination are also the same as those from the samples with no additives centrifuged immediately. Glyceraldehyde alone gave erratic results. This is noticeable when comparing the values obtained from experiments 1 and 2. The reason for the erratic nature of the inhibition of glycolysis and why it should be a¡ected by the addition of other agents remains unclear, but it is a consistent ¢nding, also demonstrated in experiment 3. Although the presence of lithium-heparin prevented clotting and consequently enabled complete mixing with glyceraldehyde, Table 2 shows that glyceraldehyde alone does not prevent a signi¢cant fall in blood glucose concentration measured after 24 h.
We have also con¢rmed previous work using sodium £uoride, showing that 50% of the loss in measurable glucose over 24 h occurs within the ¢rst 2 h. Many samples in routine practice will not reach the laboratory or be centrifuged within 2 h of sampling and it is therefore likely that the diagnosis of hypoglycaemia, impaired fasting glucose or impaired glucose tolerance may be compromised.
Conclusion
The combination of 11mmol/ L glyceraldehyde with 119 mmol/ L sodium £uoride (plus 21.7 mmol/ L potassium oxalate as anticoagulant) appears to be the best glycostatic agent. It is far superior to the conventional sodium £uoride plus potassium oxalate, and prevents signi¢cant glycolysis for at least 48 h. We recommend its use, not only in routine practice but also in studies where immediate centrifugation or analysis is not an option.
